Business context and reporting period
Inogen, Inc. develops, manufactures, markets, sells, and rents portable oxygen concentrators and related products for long-term oxygen therapy. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2021; comparative periods are the corresponding 2020 periods. Financial statement amounts below are in millions, except per-share data. The filing was signed August 4, 2021.
Financial performance and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Total revenue | $101.6 | $71.7 | $188.5 | $160.2 |
| Sales revenue | $90.3 | $65.6 | $167.4 | $148.8 |
| Rental revenue | $11.3 | $6.1 | $21.1 | $11.4 |
| Gross profit | $50.3 | $32.7 | $90.2 | $71.1 |
| Total gross margin | 49.6% | 45.7% | 47.9% | 44.4% |
| Income (loss) from operations | $11.7 | $(2.4) | $9.5 | $(4.5) |
| Net income | $5.1 | $2.6 | $4.4 | $1.0 |
| Diluted EPS | $0.22 | $0.12 | $0.19 | $0.04 |
| Adjusted EBITDA (non-GAAP) | $12.4 | $10.0 | $17.8 | $14.1 |
For the six months ended June 30, 2021, operating cash flow was $20.1 million, investing cash flow was $(3.4) million, and financing cash flow was $10.3 million. Cash and cash equivalents were $238.9 million and marketable securities were $11.1 million at June 30, 2021. Net working capital was $265.7 million. The balance sheet reports no borrowings; it includes $28.5 million of operating lease liabilities and a $19.8 million earnout liability.
Changes versus comparable periods
- Q2 revenue rose 41.7%; first-half revenue rose 17.7%. Management attributed the increases to improved consumer demand and business-to-business sales as COVID-19 impacts eased, alongside growth in rentals.
- Q2 sales revenue increased 37.6% and rental revenue increased 85.2%. First-half sales revenue increased 12.5% and rental revenue increased 84.7%. Systems sold were approximately 52,400 in Q2, up 23.3%, and 101,800 in the first half, up 6.2%.
- Gross margin improved in both periods. Management cited a higher direct-to-consumer sales mix and improved rental billable-patient mix and reimbursement rates; higher labor, materials, rental depreciation, and service costs partly offset these benefits.
- First-half operating cash flow increased from $14.1 million to $20.1 million. Cash rose by $26.9 million during the first half, including $10.9 million of proceeds from option exercises and employee stock purchases.
Outlook, risks, contingencies, and unusual items
- Supply constraints and pricing: Management expected semiconductor shortages to constrain production and prevent fulfillment of all customer demand, potentially through the second quarter of 2022. It expected higher chip costs to raise cost of goods sold beginning in Q3 2021 and planned product price increases effective September 1, 2021.
- COVID-19: Management reported recovering demand in the first half of 2021 but warned that renewed restrictions, variants, weaker consumer confidence, reduced physician access, or supply disruption could affect demand and operations.
- Medicare and TAV: In June 2021, a federal court dismissed Inogen’s complaint concerning Medicare reimbursement coding for its Tidal Assist Ventilator after finding administrative remedies had not been exhausted. The company said it would not appeal or pursue further alternatives to meet coding requirements. It reduced the earnout fair value and tested related long-lived assets; no impairment was recorded.
- Noncash valuation item: The earnout fair-value reduction generated an $8.1 million Q2 benefit and a $7.8 million first-half benefit. The earnout is contingent on future financial results and is subject to valuation estimates. Net income also reflects higher income tax expense; Q2 effective tax rate was 57.5% and first-half rate was 54.6%.
- Prior-year relief funding: Q2 and first-half 2020 results included $5.6 million of CARES Act Provider Relief Fund income, which was not received in the 2021 comparable periods.
- Reimbursement outlook: COVID-19 emergency reimbursement provisions supported rental revenue; some may expire or change. CMS proposals on DMEPOS payment methods and home oxygen coverage remained subject to regulatory decisions. Traditional Medicare fee-for-service represented 83.1% of first-half rental revenue.
- Other exposures: The company disclosed pending securities class-action and shareholder derivative litigation, customer and supplier concentration, reliance on certain single-source components, warranty obligations of $15.3 million, and approximately $65.1 million in purchase orders due within one year.
- Liquidity and guidance: Management said cash, cash equivalents, and expected operating cash generation should cover projected operating and investing needs for at least 12 months. The filing provides no specific numerical revenue or earnings guidance.
Important facts for investors to verify
- Whether chip availability, production limits, and input-cost inflation developed as expected, and whether planned price increases offset those pressures without materially reducing demand.
- How much revenue and margin growth came from sustained demand and rental additions versus temporary pandemic-related factors and reimbursement changes.
- The status and financial impact of CMS oxygen coverage and DMEPOS reimbursement decisions, including the effects of the TAV coding outcome.
- The assumptions behind the earnout valuation and the extent to which reported earnings and Adjusted EBITDA depend on noncash or other unusual items.
- Collection and credit risk: one customer represented more than 10% of first-half revenue, and two customers had net receivable balances of $10.3 million and $7.8 million at quarter-end.
- Progress and potential exposure in the securities and derivative lawsuits, and the company’s ability to manage supplier concentration and its $65.1 million of purchase orders.